Last reviewed · How we verify
Ustekinumab (UST)
Ustekinumab is a monoclonal antibody that blocks the IL-12 and IL-23 signaling pathways by binding to their shared p40 subunit, reducing inflammatory immune responses.
Ustekinumab is a monoclonal antibody that blocks the IL-12 and IL-23 signaling pathways by binding to their shared p40 subunit, reducing inflammatory immune responses. Used for Plaque psoriasis, Psoriatic arthritis, Crohn's disease.
At a glance
| Generic name | Ustekinumab (UST) |
|---|---|
| Also known as | Stelara |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Drug class | IL-12/IL-23 inhibitor monoclonal antibody |
| Target | IL-12 p40 / IL-23 p40 subunit |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Ustekinumab inhibits interleukin-12 (IL-12) and interleukin-23 (IL-23), which are key cytokines involved in T-cell differentiation and inflammatory responses. By blocking the p40 subunit common to both cytokines, it suppresses Th1 and Th17 cell-mediated inflammation, making it effective in immune-mediated inflammatory diseases. This mechanism is particularly useful in conditions driven by dysregulated T-cell responses.
Approved indications
- Plaque psoriasis
- Psoriatic arthritis
- Crohn's disease
- Ulcerative colitis
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Headache
- Fatigue
- Injection site reactions
Key clinical trials
- Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease
- VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
- De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis (PHASE4)
- The Association Between TNFSF4 Polymorphism and CD
- An Analysis of the Relationship Between the Genetic Polymorphisms of Interleukin 12 Receptor Subunit Beta 1 and Crohn's Disease in Chinese Patients
- ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar
- Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab (PHASE3)
- The Associations of Plasminogen Activator Inhibitor-1 Gene Polymorphisms With Crohn's Disease in Chinese Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: